

Supplementary Materials: Manipulation of Medicinal Products for Oral Administration to Paediatric Patients at a German University Hospital: An Observational Study

Julia Zahn *, André Hoerning, Regina Trollmann, Wolfgang Rascher and Antje Neubert *

Table S1. Examples of active substances manipulated in this study categorised according to licensing status and preventability.

License ¹	Preventability ²	Active substance	n	Alternatives ³	
1 – on-label	1a – preventable	Amlodipine	1	Amlodigamma 5 mg tablets	
		Baclofen	1	Lioresal® 5 mg tablets	
		Cholecalciferol	41	Vigantol oil 20.000 IU/mL oral drops.	
		Hydrocortisone	2	Alkindi® 5 mg granules in capsules	
		Lamotrigine	3	Lamictal 100 and 25 tablets	
		Levothyroxine	4	Eferox oral solution 100 µg/5 mL	
		Prednisolone	6	Okrido 6 mg/mL oral solution, Decortin H 10 mg tablets	
		Ursodeoxycholic acid	2	Ursofalk® 250 mg/5 mL suspension	
		1a – non-preventable	Acetylsalicylic acid	2	-
			Ferrous gluconate	5	-
Lamotrigine	2		-		
Metoprolol succinate	1		-		
Omeprazole	11		-		
Oxcarbazepine	4		-		
Valproic acid	4		-		
2 – off-label	2a – preventable	Brivaracetam	2	Briviact® 25mg/50mg tablets	
		Clonazepam	2	Rivotril® 2,5 mg/mL oral drops	
		Dexamethasone	4	Infectodexakrupp® 2 mg/5 mL liquid	

	Gabapentin	2	Gabaliqid® 50mg/mL, Neurontin 100mg hard capsules
	Hydrocortisone	1	Alkindi® 5 mg granules in capsules
	Melatonin	1	Slenyto® prolonged-release tablets
2b – non- preventable	Azathioprine	2	-
	Baclofen	5	-
	Clonidine	5	-
	Enalapril	2	-
	Esomeprazole	2	-
	Potassium bromide	4	-
	Omeprazole	13	-
	Phenobarbital	11	-
	Topiramate	10	-
	Vigabatrin	6	Kigabeq® soluble tablets (available only from 01 July 2019)

¹ License of the manipulation according to SmPC; ² Preventability by using an alternative, commercially available medicinal product; ³ Alternative commercially available medicinal product(s) that would have prevented the manipulation.